who discovered glp 1 agonists Her work paved the way for blockbuster obesity drugs. Now, she's fighting for recognition | Science Leading GLP-1 expert shares insights

7 For patients with type 2 diabetes who have atherosclerotic cardiovascular disease or are at high risk for it or who have kidney disease or heart failure, either a GLP-1 receptor agonist or an SGLT-2 inhibitor with demonstrated cardiovascular benefit with or without metformin is recommended, independent of the hemoglobin A1c level (level of evidence A)

Why North America Led the Oral Non-Peptide GLP-1 Receptor Agonist Market

Previous studies of KBP-089 using pair-feeding have demonstrated a weight loss beyond what is obtained through the reduction of appetite, and have clearly indicated that this effect likely entails increased energy expenditure, or at least a maintenance of energy expenditure, despite the reduction of food intake, a parameter known to reduce energy expenditure [12, 17, 29, 43]

By lowering inflammatory markers and oxidative stress

[DOI] [PMC free article] [PubMed] [Google Scholar] 98.Gerstein H.C., Colhoun H.M., Dagenais G.R., Diaz R., Lakshmanan M., Pais P

Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas